SRI International has been awarded a contract of up to $100 million from the National Institutes of Health's (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to support the research and development of radiation/nuclear medical countermeasures (MCMs). SRI Biosciences will provide facilities, expertise, and capabilities to advance the development of MCMs for the mitigation or treatment of acute radiation syndromes as well as the treatment of delayed effects from acute radiation exposure (ARS/DEARE) and internal radionuclide contamination. SRI researchers will also support NIAID's ongoing biodosimetry efforts.
Under the seven-year contract, SRI Biosciences will provide supportive services to NIAID's Radiation and Nuclear Medical Countermeasures Program to advance the development of candidate MCMs including biodosimetric approaches to determine radiation exposure. SRI will perform research and development studies to advance candidate MCMs toward FDA approval or licensure for ARS or DEARE.
SRI's Biosciences previous contract to develop treatments for the effects of radiation exposure ends in August 2020. The newly awarded contract is an extension of collaborative efforts with NIAID.